Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes

Cancer

Volumn 118, Issue 9, 2012, Pages 2532-2540

  Hyslop, Terry ^a   Weinberg, David S ^b   Schulz, Stephanie ^a   Barkun, Alan ^c   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

colorectal cancer; guanylyl cyclase C; molecular staging; occult tumor burden; racial disparities; RT qPCR

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GUCY2C GENE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; OBSERVATIONAL STUDY; OCCULT CANCER; ONCOGENE; OUTCOME ASSESSMENT; POPULATION RISK; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA ISOLATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GUANYLATE CYCLASE; HEALTH STATUS DISPARITIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SURVIVAL RATE; TUMOR BURDEN;

EID: 84860224916     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26516     Document Type: Article

References (49)

1. Compton CC, Greene FL,. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54: 295-308.
2. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010; 375: 1030-1047.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A,. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2009.
4. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
5. Soneji S, Iyer SS, Armstrong K, Asch DA,. Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am J Public Health. 2010; 100: 1912-1916.
6. Chien C, Morimoto LM, Tom J, Li CI,. Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer. 2005; 104: 629-639.
7. Le H, Ziogas A, Lipkin SM, Zell JA,. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1950-1962.
8. Marcella S, Miller JE,. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J Clin Epidemiol. 2001; 54: 359-366.
9. Mayberry RM, Coates RJ, Hill HA, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst. 1995; 87: 1686-1693.
10. Polite BN, Dignam JJ, Olopade OI,. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005; 89: 771-793.
11. White A, Vernon SW, Franzini L, Du XL,. Racial disparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics? Cancer. 2010; 116: 4622-4631.
12. Chen VW, Fenoglio-Preiser CM, Wu XC, et al. Aggressiveness of colon carcinoma in blacks and whites. National Cancer Institute Black/White Cancer Survival Study Group. Cancer Epidemiol Biomarkers Prev. 1997; 6: 1087-1093.
13. Iddings D, Ahmad A, Elashoff D, Bilchik A,. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol. 2006; 13: 1386-1392.
14. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ,. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn. 2007; 9: 563-571.
15. Bilchik AJ, Hoon DS, Saha S, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg. 2007; 246: 568-575; discussion 575-567.
16. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998; 339: 223-228.
17. Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA,. Molecular staging estimates occult tumor burden in colorectal cancer. Adv Clin Chem. 2010; 52: 19-39.
18. Waldman SA, Hyslop T, Schulz S, et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA. 2009; 301: 745-752.
19. Li P, Schulz S, Bombonati A, et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 2007; 133: 599-607.
20. Pitari GM, Li P, Lin JE, et al. The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther. 2007; 82: 441-447.
21. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA,. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005; 36: 170-179.
22. Cagir B, Gelmann A, Park J, et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med. 1999; 131: 805-812.
23. Carrithers SL, Barber MT, Biswas S, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA. 1996; 93: 14827-14832.
24. Schulz S, Hyslop T, Haaf J, et al. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res. 2006; 12: 4545-4552.
25. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA,. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res. 2011; 17: 3293-3303.
26. Beaulieu M, Desaulniers M, Bertrand N, et al. Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer. Diagn Mol Pathol. 2010; 19: 20-27.
27. Haince JF, Houde M, Beaudry G, et al. Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. J Clin Pathol. 2010; 63: 530-537.
28. Sargent DJ, Resnick MB, Meyers MO, et al. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis [published online ahead of print May 1, 2011]. Ann Surg Oncol. PMID: 21533822.
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97: 1180-1184.
30. Chervoneva I, Li Y, Iglewicz B, Waldman S, Hyslop T,. Relative quantification based on logistic models for individual polymerase chain reactions. Stat Med. 2007; 26: 5596-5611.
31. Therneau TM, Atkinson EJ,. An introduction to recursive partitioning using the rpart routines. Technical report 61. Rochester, MN: Mayo Clinic; 1997.
32. Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC, O'Connell MJ,. Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer. 2010; 116: 1691-1698.
33. Biesheuvel CJ, Vergouwe Y, Steyerberg EW, Grobbee DE, Moons KG,. Polytomous logistic regression analysis could be applied more often in diagnostic research. J Clin Epidemiol. 2008; 61: 125-134.
34. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17: 857-872.
35. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003; 21: 2912-2919.
36. Swanson RS, Compton CC, Stewart AK, Bland KI,. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003; 10: 65-71.
37. Berry J, Bumpers K, Ogunlade V, et al. Examining racial disparities in colorectal cancer care. J Psychosoc Oncol. 2009; 27: 59-83.
38. Polite BN, Dignam JJ, Olopade OI,. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006; 24: 2179-2187.
39. Laiyemo AO, Doubeni C, Pinsky PF, et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst. 2010; 102: 538-546.
40. Alexander D, Jhala N, Chatla C, et al. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer. 2005; 103: 2163-2170.
41. Ashktorab H, Schaffer AA, Daremipouran M, Smoot DT, Lee E, Brim H,. Distinct genetic alterations in colorectal cancer. PLoS One. 2010; 5: e8879.
42. Ashktorab H, Smoot DT, Carethers JM, et al. High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res. 2003; 9: 1112-1117.
43. Ashktorab H, Smoot DT, Farzanmehr H, et al. Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer. 2005; 116: 914-919.
44. Grizzle WE, Manne U, Weiss HL, Jhala N, Talley L,. Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 and p27(kip-1). Int J Cancer. 2002; 97: 403-409.
45. Freeman HP,. The meaning of race in science-considerations for cancer research: concerns of special populations in the National Cancer Program. Cancer. 1998; 82: 219-225.
46. Witzig R,. The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med. 1996; 125: 675-679.
47. Ogino S, Nosho K, Irahara N, et al. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol. 105: 420-433.
48. Meyerhardt JA, Mayer RJ,. Systemic therapy for colorectal cancer. N Engl J Med. 2005; 352: 476-487.
49. Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370: 2020-2029.